Análisis de la acción Supernus Pharmaceuticals Inc (SUPN)SUPNSupernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Supernus Pharmaceuticals Inc is currently trading at $40.70, which is significantly below the analyst price target of $67, suggesting potential upside. However, the RSI is at 45.91, indicating a neutral momentum, and the company has reported a net loss of over $58 million in the latest quarter, raising concerns about profitability. The upcoming earnings report on October 29 could provide more clarity on its financial health and impact investor sentiment.

8 analysts cover SUPN: 6 rate it Buy, 2 Hold and 0 Sell. The average price target is 61.33.